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Abstract 
Purpose: To evaluate the efficacy and the safety of the enzymatic vitreolysis with a single intravitreal injection of ocriplasmin 125 
μg across a group of patients with symptomatic vitreomacular adhesion (sVMA) during 6 months follow up. 
Design: A randomized, placebo-controlled, double-masked, 6-month follow up study. 
Participants: A total of 28 patients (12 M / 16F) (19 receiving ocriplasmin; 9 receiving placebo), mean aged 71 years old, 
diagnosed with sVMA, VMT, FTMH  e ERM by optical coherence tomography. 
Methods: A single intravitreal injection of ocriplasmin 125 μg or placebo. Primary endpoint was sVMA resolution or FTMH 
closure. Secondary endpoint included the integrity of the external membrane and the inner and outer segments of the photoreceptor 
interface using OCT. The evaluation was carried out at baseline and during 6 months after intravitreal injection of ocriplasmin or 
placebo.  
Results: After a 6 months follow-up period, the rate of VMA resolution was 42.1% in the Ocriplasmin group vs the 22% in the 
placebo group. FTMH closure rate was 50% in the Ocriplasmin group vs 0% in the placebo group. The best results were optained 
within 28 days from the treatment. No case of uveitis, endophthalmitis, retinal tears, retinal detachment or bleeding during follow-
up were reported. One patient reported  floaters and transitional photopsias. 
Conclusions: The study confirmed the efficacy and safety of Ocriplasmin injection for patients with VMT, including when 
associated with full-thickness macular holes during six months follow up.  Long term studies are certainly needed to confirm these 
results. 
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Introduction 
    Vitreous body is a gel that ensures the volume and the 
stability of the eye.  
It is made by a mixture of water and an heterogeneous 
texture formed by collagen fibrils of types II, V, XI and  
IX and hyaluronic acid fibers, that maintain the gel 
structure [1]. 
    A few cells called ialocites located in the cortex, 
especially at the level of the base of the vitreous and in 
the zonular region. They are more numerous in the 
young adult and decrease with age [2].  Posterior vitreous  
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cortex contracted close relations with the macula, the 
nobel part of the retina, forming a complex anatomical 
unit known as vitreoretinal interface (VRI) [3]. 
    The progressive vitreal syneresis with aging and 
vitreoretinal adhesions weakening lead to separation of 
the posterior cortex from the internal limiting membrane 
of the retina (ILM), phenomenon known as posterior 
vitreous detachment (PVD). 
In the majority of cases, PVD remains asymptomatic or it 
causes symptoms such as floaters, cobwebs, without other 
complications [4]. 
 
     However, in a few cases, the persistence of  VMA 
exerting tractional forces (vitreomacular traction, VMT) 
may be associated with distortion of the macular 
architecture. Patients report symptoms such as blurred 
vision, photopsia, metamorphopsia or, in the final stages, 
a decrease in visual acuity leaded by the development of 
cystoid macula edema or macular hole. (Symptomatic 
vitreomacular adhesion, sVMA). 
Only in this stage, VMA can determine a pathological 
process for macular anatomy [5]. 
Optical coherence tomography (OCT) explained the 
patogenesis of the VMT, improved the diagnostic 
accuracy and therefore the appropriateness of therapies 
[6]. 
 
    Until few years ago pars plana vitrectomy with or 
without removeal of the ILM (ILM peeling) was the gold 
standard for the treatment of VMT. However, as surgical 
procedure, it is associated with possible complications 
such as infection, bleeding, retinal detachment, cataract 
in phakic patients [7]. 
 
Pharmacologic Vitreolysis with enzimes, which can result 
in the liberation of VMT, facilitating the induction of a 
PVD, opened new fronteers for the treatment of VMT 
[8]. 
    Many drugs like collagenase, dispase, natokinase, 
hyaluronidase, plasmin and plasminogen activator have 
been purposed as vitreolytic agents [9-14]. 
Ocriplasmin is a truncated subunit of human plasmin 
with aspecific proteolytic activity, capable of inducing 
liquefaction of the vitreous and separation of the vitreous 
cortex from retina [15]. 
 
    Ocriplasmin (Jetrea, ThromboGenics) was approved 
for intravitreal use for the treatment of symptomatic 
VMT and MH by the Food and Drug Administration 
(FDA) in the United States, in November 2012 and by  
 
 
 
 
 
 
 
the European Medicines Agency (EMA) in May 2013 
[16]. 
    In this study we presented the results about 
effectiveness and safety of a single intravitreal injection of 
ocriplasmin 125 μg across a group of patients with 
symptomatic vitreomacular adhesion (sVMA) during 6 
months follow up. 
 
 
Materials and methods 
 
    The study was designed as randomized, double-blind, 
placebo-controlled and was carried out in the 
Ophtalmology Department of '' Sapienza”  University' of 
Rome. We selected 28 patients, 12 males and 16 females, 
aged between 62 and 81 years (mean age 71 years old). 
All eyes were diagnosed of sVMA, highlighted by OCT. 
22 eyes were phakic and 6 eyes were pseudophakic. 8 
pakic patients of the total had full-thickness macular hole 
(FTMH). Five of these also suffered of ERM. 11 patients 
(9 phakic and pseudophakic 2) were diagnosed of 
epiretinal membrane (ERM) by OCT. 
 
    Inclusion criteria were: age of 18 years or older; focal 
sVMA diagnosed with OCT, BSCVA equal to or less 
than 20/25 (0.1 logMAR) based on the tables of 
Treatment of Early diabetic Retinopathy Study 
(ETDRS).		
	
    Patients with proliferative diabetic retinopathy, 
macular degeneration, retinal vascular occlusion, aphakia, 
high myopia (more than -8 diopters), uncontrolled 
glaucoma by therapy, macular hole above 400 uM in 
diameter, vitreous opacities, zonular instability, history of 
retinal detachment, recent vitrectomy, recent macular 
laser photocoagulation were excluded from the study. 
    The purpose of the study was to evaluate the efficacy 
and safety of a single injection of Ocriplasmin 125 
micrograms in proteolytic resolution of symptomatic 
sVMA or FTMH closure.  
    Also the integrity of the external membrane and the 
inner and outer segments of the photoreceptor interface 
were evaluated using OCT. 
 
 
    The evaluation was carried out at baseline and during 
6 months after intravitreal injection of ocriplasmin 
(Table A) or placebo (Table B). 
 
 
 
 
 
 
Pacella F, Nikolakopoulos K, Nikolakopoulos A.  et  al.	
www.sensesandsciences.com	
	
 
Table B  
Placebo subgroup: data at time of enrollment (t0) and during 6 months of follow up 
 
Pt	 Age	 Sex Lens BCVA 
T0 
BCVA 
28 days 
after 
injection 
FTMH ERM VMA 
(μm) 
 
PVD PVD 
(day after 
injection) 
Vitrectomy
1	 64	 F Phakic 20/40 20/25 - - 200 + 28 -
2	 69	 F Phakic 20/60 20/60 - - 281 + 90 -
3	 80	 M Pseudo-
Phakic 
20/40 20/50 - - 164 - - +
4	 73	 F Phakic 20/80 20/100 + - 650 - - +
5	 67	 M Phakic 20/100 20/100 - - 840 - - +
6	 77	 F Phakic 20/60 20/50 + + >1500 - - +
7	 71	 M Phakic 20/80 20/80 - - 400 - - +
8	 67	 M Pseudo-
Phakic 
20/40 20/50 - + 384 - - +
9	 72	 M Phakic 20/25 20/30 - + 120 - - +
	 	      
 
Table A  
Ocriplasmin subgroup: data at time of enrollment (t0) and during 6 months of follow up 
	
Pt Age Sex Lens BCVA 
T0 
BCVA
28 days 
after 
injection 
FTMH ERM VMA 
(μm) 
 
PVD PVD 
(days 
after 
injection) 
Vitrectomy
1 68 F Phakic 20/25 20/20 _ - 435 + 1 -
2 70 F Phakic 20/50 20/40 - + 282 + 68 -
3 71 M Phakic 20/100 20/30 + + 250 + 28 -
4 57 F Phakic 20/40 20/30 - - 450 + 21 -
5 74 M Phakic 20/60 20/40 + - 391 + 42 -
6 76 M Phakic 20/25 20/25 - + 600 + 14 -
7 68 M Phakic 20/60 20/25 + - 115 + 2 -
8 68 F Phakic 20/60 20/60 + - 300 + 28 +
9 65 M Phakic 20/30 20/25 - - 377 - - +
10 62 F Phakic 20/50 20/40 + + 120 - - +
11 75 F Pseudo-
Phakic 
20/80 20/60 - - 250 - - +
12 77 F Phakic 20/50 20/50 - - 497 - - +
13 76 M Phakic 20/200 20/200 - + >1500 - - +
14 68 F Phakic 20/60 20/60 + + 100 - - +
15 79 M Pseudo-
Phakic 
20/80 20/80 - + >1500 - - +
16 81 F Phakic 20/60 20/60 - + >1500 - - +
17 70 F Phakic 20/70 20/200 - - 400 - - +
18 81 M Pseudo-
Phakic 
20/50 20/40 - - 878 - - +
19 67 F Pseudo-
Phakic 
20/40 20/40 - + 398 - - +
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Treatment was randomized with a single intravitreal 
injection of ocriplasmin or placebo. Before signing 
informed consent, all patients were informed extensively 
on the benefits and possible complications of the 
injection. Institutional Review Board (IRB)/Ethics 
Committee approval was obtained.  The ratio of 
administration of ocriplasmin and placebo was 2:1. 19 
patients received the ocriplasmin and 9 placebo. All 
implants were performed under sterile operating room 
conditions, using 5% povidone–iodine solution, topical 
anesthetic with ropivacaine [17]. 
The single intravitreal injection contained 125 
micrograms of ocriplasmin in 0.10 ml of solution. The 
injection of placebo contained 0.10 ml withdrawn in the 
same way and containing the same saline solution 
without the ocriplasmin.  Postoperative therapy consisted 
in ofloxacin drops 4 times a day for 7 days after the 
treatment. All patients were monitored for local or 
systemic adverse effects relative to the implant for the 
duration of the whole study. 
    The evaluations were performed at the moment of 
enrollment and during a follow up period which included 
the first day after the injection (T0), 7 days after injection 
(T1), 14 days after injection (T2), 28 days after injection 
(T3), 90 days after injection (T4) and 180 days after 
injection (T5). Each evaluation included best corrected 
visual acuity (BCVA) by the boards of ETDRS placed at 
distance of 4 meters, biomicroscopy with a slit lamp, 
measuring intraocular pressure (IOP) with Goldman 
applanation tonometry, binocular indirect 
ophthalmoscopy after pupillary dilation, B-scan 
ultrasonography, Spectralis HRA-OCT Heidelberg 
Engineering, fundus photography. 
Patients compiled the National Eye Institute Visual 
Functioning Questionnaire-25 (VFQ-25), Version 2000.      
    We considered the efficacy of the injection as a mean 
improvement of BCVA≥ 10 letters (2 lines).  
Pars plana vitrectomy was considered when patient 
presented one of the following parameters: worsening of 
the underlying disease; visual acuity decrease of more 
than two lines on boards of ETDRS; no improvement 28 
days after injection. 
 
Results 
 
    Data about results are summarized in Tables A 
(Ocriplasmin group) and B (Placebo group). 
The primary endpoint of the study was the resolution of 
sVMA after a single injection of 125 micrograms of 
Ocriplasmin. After a 6 months follow-up period, 42.1% 
of patients of the Ocriplasmin group had a complete 
resolution of VMA compared to the 22% in the placebo 
group. 
    Considering the subgroup of phakic patients, the 
resolution of VMA were found in 34.2% of patients of 
Ocriplasmin group compared to the 25% of the placebo 
group. Among the pseudophakic patients any resolution 
of VMA was observed. 
    In the Ocriplasmin group, two of eight patients with 
ERM (25%) and five of eleven without ERM (45%) had 
a non-surgical resolution of VMA compared to the 0% 
and 33 % respectively in the placebo group. Four of six 
patients (66.2%) affected by FTMH treated with 
Ocriplasmin had resolution of VMA and three of these 
(50%) achieved complete closure of the hole. Four (31%) 
of the remaining patients without MH, had the 
resolution of VMA. 
    Two patients in the placebo group, affected by 
FTMH, had not clinical improvement. 
    The mean BSCVA of all patients was 63 letters on the 
EDTRS boards (0.38 to 0.48 logMAR;  Snellen from 
20/50 to 20/60). 
In the Ocriplasmin group, BSCVA remained unchanged 
in 42.1% of patients.  
Eight patients had a modest improvement (less than 2 
EDTRS lines) and two patients had a significant 
improvement (more than three EDTRS lines). Only one 
patient of all groups had visual impairment from 20/70 
to 20/200, leading by the progression of the VMT in 
FTMH. Patients who had been given placebo had no 
significant improvement or loss of visual acuity. 
    Regarding safety, any case of uveitis, endophthalmitis, 
retinal tears, retinal detachment or bleeding during 
follow-up were reported. One patient reported  floaters 
and transitional photopsias. 
 
Discussion 
 
   Ocriplasmin intravitreal injection represents a new 
therapeutical option that can contribute to a better 
management of vitreoretinal interface diseases. Our 
results about incidence of VMA resolution are consistent 
with data reported in Literature [18]. In our study the 
rate of  VMA resolution was 42%. Pharmacologic action 
of ocriplasmin appeared to be greater in the first month 
after the injection. In fact, the most improvement has 
occurred during the first 28 days of treatment and 
remained stable in the subsequent six months (Fig.1). 
    Clinical features as VMA diameter of less than 1.500 
micron, presence of a full-thickness macular hole 
(FTMH), age <65 years old and being phakic patient are 
critical for a better response to therapy. 
The main symptom of  VMT is the decrease in BCVA. 
BCVA improvement in the Ocriplasmin group was 
superior to placebo group. It could appear a modest 
improvement. However , in these patients, mean 
preoperative BCVA was  relatively good (64 ETDRS 
letters corresponding to 20/50 on the Snellen scale). At 
the same time, patients with a poor preoperative BCVA 
had a significant visual recovery (three or more lines of 
letters on EDTRS chart). 
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    This could seem a limitation of the study, but early 
treatment of VMT could prevent the progression of the 
disease indeed.  
No adverse effects related to Ocriplasmin injection were 
observed during the follow-up period, even though 
retinal tears, retinal detachment, vitreitis and bleeding 
were reported in the Literature [19]. One patient 
complained of floaters and photopsias, but they were 
transient symptoms and resolved during the follow-up 
     Figure 1 
    Figure 2: VMA resolution rate 
     Figure 3: FTMH closure rate 
period. At 6 months follow-up, Ocriplasmin  resulted 
efficient, with substantial improvements in BCVA values  
due to a significant  resolution of VMT (Fig.2) and 
FTMH (Fig.3).  
    About the safety profile, the drug resulted well 
tolerated and  no complications related to the injection 
nor the drug itself emerged, in accordance with Literature 
[20-21]. 
42%
27%
22%
14%
Study MIVI-TRUST
Ocriplasmin Placebo
50%
44%
0%
11%
Study MIVI-TRUST
Ocriplasmin Placebo
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    In conclusion, our study confirms that ocriplasmin 
injection represents an efficient and safe treatment option 
for patients with VMT, including when associated with 
full-thickness macular holes ≤400 μm in diameter. These 
results are stable during six months. Long term studies 
are certainly needed to confirm these results 
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